AR020080A1 - UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA - Google Patents
UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICAInfo
- Publication number
- AR020080A1 AR020080A1 ARP990102534A ARP990102534A AR020080A1 AR 020080 A1 AR020080 A1 AR 020080A1 AR P990102534 A ARP990102534 A AR P990102534A AR P990102534 A ARP990102534 A AR P990102534A AR 020080 A1 AR020080 A1 AR 020080A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine
- equine encephalitis
- venezuelan equine
- encephalitis virus
- vee
- Prior art date
Links
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 title abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000700618 Vaccinia virus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describe una vacuna para la inmunizacion terapéutica o profiláctica para uso en la proteccion de mamíferos, como por ejemplo, humanos o animales contrael virus Encefalitis Equina Venenzolana (VEE). En particular, la vacuna comprende un virus recombinante, tal como un virus vaccinia recombinante que sea capazde expresar los genes estructurales del VEE en forma atenuada, que se ha modificado para aumentar el efecto protector de la vacuna. Estos se logra pormodificacion de la secuencia de la cepa del VEE atenuada y/o poniendo esto bajo control de promotor modificado, lo cual aumenta la expresion del vector. Ademásse describen una composicion farmacéutica de la vacuna, así como también una vacuna multivalente y el uso de un vector que incluye una secuencia que codificauna forma atenuada del virus de Encefalitis Equina Venezolana (VEE) para la manufactura de un medicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9811433A GB2337755B (en) | 1998-05-29 | 1998-05-29 | Virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020080A1 true AR020080A1 (es) | 2002-04-10 |
Family
ID=10832820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102534A AR020080A1 (es) | 1998-05-29 | 1999-05-28 | UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6936257B1 (es) |
| EP (1) | EP1084261B8 (es) |
| AR (1) | AR020080A1 (es) |
| AT (1) | ATE275631T1 (es) |
| AU (1) | AU3834999A (es) |
| BR (1) | BR9910814A (es) |
| CA (1) | CA2329133C (es) |
| DE (1) | DE69920011T2 (es) |
| DK (1) | DK1084261T3 (es) |
| ES (1) | ES2224655T3 (es) |
| GB (1) | GB2337755B (es) |
| MX (1) | MXPA00011708A (es) |
| PT (1) | PT1084261E (es) |
| WO (1) | WO1999063098A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| CA2401974C (en) | 2000-03-02 | 2013-07-02 | Emory University | Dna expression vectors and methods of use |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| DE60234018D1 (de) * | 2001-03-08 | 2009-11-26 | Univ Emory | Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene |
| DE602004000851T2 (de) * | 2003-10-30 | 2007-05-16 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Akustisch gekoppelter Dünnschicht-Transformator mit zwei piezoelektrischen Elementen, welche entgegengesetzte C-Axen Orientierung besitzten |
| WO2008101349A1 (en) * | 2007-02-23 | 2008-08-28 | Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence | Recombinant viral vectors for prevention and protection against alphavirus infection |
| JP5908397B2 (ja) * | 2009-06-09 | 2016-04-26 | デフィルス、インコーポレイテッドＤｅｆｙｒｕｓ， Ｉｎｃ． | 病原体感染を予防又は治療するためのインターフェロン投与 |
| CA2826920A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
| MX350795B (es) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
| WO2013151567A1 (en) * | 2012-04-04 | 2013-10-10 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research Institute Of Infectious Diseases | Equine encephalitis virus vaccines and methods of using thereof |
| LT2850431T (lt) | 2012-05-16 | 2018-06-25 | Immune Design Corp. | Vakcinos, skirtos hsv-2 |
| ES2655442T3 (es) * | 2012-11-05 | 2018-02-20 | Regeneron Pharmaceuticals, Inc. | Animales no humanos modificados genéticamente y métodos de uso de los mismos |
| EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| ES2921605T3 (es) | 2016-01-29 | 2022-08-30 | Bavarian Nordic As | Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante |
| KR20230051602A (ko) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| NZ746934A (en) | 2016-04-15 | 2023-11-24 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018170026A2 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| DK3596116T5 (da) | 2017-03-16 | 2024-09-02 | Alpine Immune Sciences Inc | Variante immunmodulatoriske pd-l1-proteiner og anvendelser deraf |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| JP7291398B2 (ja) | 2017-03-30 | 2023-06-15 | ザ ユニバーシティー オブ クイーンズランド | キメラ分子およびその使用 |
| EP4400174A3 (en) | 2017-09-01 | 2024-10-23 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
| EP4442268A2 (en) | 2017-10-10 | 2024-10-09 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| US20200283500A1 (en) | 2017-10-18 | 2020-09-10 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| AU2019345151A1 (en) | 2018-09-19 | 2021-04-29 | Alpine Immune Sciences, Inc. | Methods and uses of variant CD80 fusion proteins and related constructs |
| AU2019389151A1 (en) | 2018-11-30 | 2021-06-10 | Alpine Immune Sciences, Inc. | CD86 variant immunomodulatory proteins and uses thereof |
| BR112021020447A2 (pt) | 2019-04-17 | 2022-05-17 | Alpine Immune Sciences Inc | Métodos e usos de proteínas de fusão de ligante icos variante (icosl) |
| CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
| PE20240641A1 (es) | 2021-05-07 | 2024-04-04 | Alpine Immune Sciences Inc | Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185440A (en) * | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| US5505947A (en) * | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US6261570B1 (en) * | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
-
1998
- 1998-05-29 GB GB9811433A patent/GB2337755B/en not_active Revoked
-
1999
- 1999-05-05 PT PT99920967T patent/PT1084261E/pt unknown
- 1999-05-05 AU AU38349/99A patent/AU3834999A/en not_active Abandoned
- 1999-05-05 CA CA2329133A patent/CA2329133C/en not_active Expired - Fee Related
- 1999-05-05 WO PCT/GB1999/001387 patent/WO1999063098A1/en active IP Right Grant
- 1999-05-05 DE DE69920011T patent/DE69920011T2/de not_active Expired - Lifetime
- 1999-05-05 BR BR9910814-3A patent/BR9910814A/pt not_active IP Right Cessation
- 1999-05-05 DK DK99920967T patent/DK1084261T3/da active
- 1999-05-05 EP EP99920967A patent/EP1084261B8/en not_active Expired - Lifetime
- 1999-05-05 AT AT99920967T patent/ATE275631T1/de active
- 1999-05-05 ES ES99920967T patent/ES2224655T3/es not_active Expired - Lifetime
- 1999-05-05 MX MXPA00011708A patent/MXPA00011708A/es active IP Right Grant
- 1999-05-05 US US09/701,299 patent/US6936257B1/en not_active Ceased
- 1999-05-05 US US11/892,970 patent/USRE41745E1/en not_active Expired - Fee Related
- 1999-05-28 AR ARP990102534A patent/AR020080A1/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| GB9811433D0 (en) | 1998-07-22 |
| WO1999063098A1 (en) | 1999-12-09 |
| DE69920011D1 (de) | 2004-10-14 |
| US6936257B1 (en) | 2005-08-30 |
| CA2329133C (en) | 2011-07-12 |
| EP1084261B1 (en) | 2004-09-08 |
| PT1084261E (pt) | 2005-01-31 |
| AU3834999A (en) | 1999-12-20 |
| DK1084261T3 (da) | 2005-01-17 |
| GB2337755A (en) | 1999-12-01 |
| DE69920011T2 (de) | 2005-09-15 |
| CA2329133A1 (en) | 1999-12-09 |
| BR9910814A (pt) | 2001-02-13 |
| ATE275631T1 (de) | 2004-09-15 |
| GB2337755B (en) | 2003-10-29 |
| EP1084261A1 (en) | 2001-03-21 |
| ES2224655T3 (es) | 2005-03-01 |
| MXPA00011708A (es) | 2005-10-13 |
| USRE41745E1 (en) | 2010-09-21 |
| EP1084261B8 (en) | 2004-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR020080A1 (es) | UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA | |
| CO2017010831A2 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
| BR9912410A (pt) | Vacina para imunização de aves, e, processos para imunizar uma ave e para preparar uma vacina para imunizar uma ave | |
| CO2021012380A2 (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| ITMI20021527A1 (it) | Anticorpi anti componente c5 del complemento e loro uso | |
| BR112018076633A2 (pt) | mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk | |
| ES2746960T3 (es) | Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos | |
| CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
| FI935174A (fi) | Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem | |
| AR100419A1 (es) | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| AR105482A1 (es) | Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso | |
| WO2010068968A8 (en) | Methods and compositions for use of a coccidiosis vaccine | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| ES2676542T3 (es) | Composiciones de CDV recombinante y usos de las mismas | |
| ES2117029T3 (es) | Vacuna contra la coccidiosis aviar. | |
| MX2022010372A (es) | Vacuna contra la infeccion por el virus de la peste porcina africana. | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| ZA202202986B (en) | Agent for induction of specific immunity against severe acute respiratory syndrome coronavirus (sars-cov-2) in liquid form (versions) | |
| CO2020013690A2 (es) | Composiciones y métodos para el tratamiento de la distrofia macular | |
| BRPI0416916A (pt) | promotores para expressão em vìrus de vacìnia modificada ankara | |
| CO6361950A2 (es) | Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1 | |
| ES2074280T3 (es) | Metodo para modificar el tropismo de celula, tejido o huesped de un microorganismo, microorganismos recombinantes obtenidos de este modo y su uso en medicina y medicina veterinaria. | |
| MX2022001028A (es) | Vacuna de la fiebre porcina africana. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |